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Modeling late-onset disorders such as Parkinson’s
disease (PD) using iPSC technology remains a chal-
lenge, as current differentiation protocols yield cells
with thepropertiesof fetal-stagecells.Here,we tested
whether it is possible to accelerate aging in vitro to
trigger late-onset disease phenotypes in an iPSC
model of PD. In order to manipulate a factor that is
involved in natural aging aswell as in premature aging
syndromes, we used telomere shortening as an age-
inducing tool. We show that shortened telomeres
result in age-associated as well as potentially dis-
ease-associated phenotypes in human pluripotent
stem cell (hPSC)-derived midbrain dopamine (mDA)
neurons. Our approach provides proof of concept
for the further validation of telomere shortening
as an induced-aging tool for late-onset-disease
modeling.INTRODUCTION
Induced pluripotent stem cell (iPSC) lines derived from patients
affected by genetic disease represent a powerful tool for disease
modeling and drug discovery. Modeling of early developmental
disorders of the nervous system has been successful for several
disorders such as spinal muscular atrophy, familial dysautono-
mia, or primary herpes simplex encephalitis (Ebert et al., 2009;
Lafaille et al., 2012; Lee et al., 2009) among others. In contrast,
the modeling of late-onset disorders, such as Alzheimer’s (AD)
and Parkinson’s (PD) raises additional challenges such as the
ability to faithfully recapitulate disease phenotypes that occur
only late in life (Srikanth and Young-Pearse, 2014). A potential
reason underlying this challenge is the reset of donor age in hu-
man pluripotent stem cells during somatic cell reprogramming
(Mahmoudi and Brunet, 2012). Thus, the ability to induce
‘‘age’’ in iPSC-based models may be an important tool for the
study of late-onset disease. Our lab recently presented a strat-
egy to artificially induce aging in vitro for late-onset disease
modeling. Using a model of PD, we engineered the expression1184 Cell Reports 17, 1184–1192, October 18, 2016 ª 2016 The Auth
This is an open access article under the CC BY license (http://creativeof the protein progerin in iPSC-derived midbrain dopamine
(mDA) neurons, the cell predominantly affected in PD (Miller
et al., 2013). We showed that PROGERIN expression induces
both general aging-associated phenotypes such as abnormal
nuclear morphologies and accumulation of DNA damage and
ROS as well as features more specific to neuronal aging such
as shorter dendrites. Adding the ‘‘aging’’ factor to the genetic
vulnerability of PD iPSC also enhances relevant phenotypes of
PD such as the progressive loss of tyrosine hydroxylase (TH)
expression, which is the rate-limiting enzyme in the synthesis
of dopamine (DA) (Miller et al., 2013). However, it remains unclear
whether the aging phenotype induced by progerin mimics phys-
iological or pathological aging. With the objective of manipu-
lating a factor more closely associated to physiological aging,
we propose here telomere shortening as an alternative aging
inducing tool.
Telomere attrition is one of the best knownmechanisms of ag-
ing, both in human (Harley et al., 1990) and mice (Flores et al.,
2008). Telomeres are special nucleoprotein structures at the
ends of eukaryotic chromosomes (Wellinger and Sen, 1997)
that protect them from degradation and DNA damage (Chan
and Blackburn, 2002; Palm and de Lange, 2008). When cells
divide, the telomeres are not fully replicated, leading to telomere
shortening with every replication. The main mechanism to coun-
teract shortening is telomere elongation via the enzyme telome-
rase, a reverse transcriptase that can elongate telomeres de
novo after each cell division (Greider and Blackburn, 1985). Telo-
merase is activated during fetal development (Wright et al.,
1996). However, after birth, telomerase is repressed in most
somatic tissue (Blasco et al., 1995), and, as a consequence,
progressive telomere erosion occurs in most somatic cells
throughout life. Some cell types, such as stem cells and germ
cells, retain moderate telomerase activity levels. However, those
levels are often not sufficient to prevent telomere shortening with
aging (Flores et al., 2008). Critically short telomeres can trigger a
persistent DNA damage response, which leads to cellular senes-
cence and/or apoptosis (Blasco, 2005). Those cellular changes
compromise tissue function and the capacity for regeneration,
factors that contribute to organismal aging (Canela et al.,
2007). Progressive telomere shortening has been proposed to
represent a ‘‘molecular clock’’ that underlies organism aging.
Several well-known premature aging disorders in humans suchors.
commons.org/licenses/by/4.0/).
as dyskeratosis congenita (DC) are characterized by a faster rate
of telomere attrition. DC patients carry mutations in components
of the telomerase complex, which result in decreased telome-
rase stability and telomere length (Mitchell et al., 1999). DC pa-
tients develop multiple pathologies over time such as defects
of the skin and the hematopoietic system, bone marrow failure,
and premature death (Blasco, 2005).
The concept of telomeres as a mitotic clock in proliferating so-
matic cells has been supported by several studies, which
strongly argue for a major role of telomeres in replicative aging.
However, the role of telomeres in non-dividing cells such as neu-
rons remains obscure. There is considerable evidence for a link
between short telomeres or changes in telomere-associated
proteins with neurodegeneration. Of notice, mutations in the
telomere-associated proteins (TRF2 interacting proteins) ATM,
WRN, and NBS1 are responsible for human neurological disor-
ders characterized by developmental abnormalities. Those
include increased risk for various cancers, signs of premature
aging and telomere shortening below a critical length. Interest-
ingly, these pathologies present in human patients have been
modeled in mice only when studied in combination with telome-
rase deficiency and short telomeres in the context of the telome-
rase-deficient mouse model (Blasco, 2005). These data support
the idea that short telomeres can trigger premature aging as well
as neurodegeneration (Barlow et al., 1996; Chang et al., 2004;
Lebel and Leder, 1998; Ranganathan et al., 2001; Wong et al.,
2003). In the other hand, treatment of old mice with adeno-asso-
ciated virus (AAV) expressing mouse TERT delays physiological
aging and extends longevity by improving health and fitness
(Bernardes de Jesus et al., 2012). Furthermore, it has been
shown that reactivation of telomerase in old, advanced genera-
tion (G4) mice of an inducible-TERT knockin mouse model can
reverse neurodegeneration phenotypes associated with the
accelerated aging phenotype in those mice (Jaskelioff et al.,
2011). Finally, individuals with short telomeres in peripheral
blood mononuclear cells (PBMCs) appear to be more prone to
neurodegenerative disorders such as AD, PD, and dementia
(Grodstein et al., 2008; Guan et al., 2012; Hochstrasser et al.,
2012; Honig et al., 2006, 2012; Jenkins et al., 2006; Kume
et al., 2012; Maeda et al., 2012; Martin-Ruiz et al., 2006; Panos-
sian et al., 2003; Thomas et al., 2008; von Zglinicki et al., 2000;
Watfa et al., 2011). Considering that telomere length is thought
to be proportional within individuals across different organs,
these data support an association between telomere length
and neurodegeneration.
In the current study, we aim to test telomere shortening as an
induced aging tool in neurons by testing whether iPSC-derived
mDA with shortened telomeres exhibit age- or disease-related
phenotypes in a model of Parkinson’s disease.
RESULTS
Telomere Dynamics in Neural Differentiation
As a first step toward generating neural cells with reduced telo-
mere length by telomerase downregulation, we set out to define
the best time point for downregulating telomerase. Therefore, we
measured telomere length and the dynamics of telomerase ac-
tivity during neuronal differentiation in vitro.We initially measuredtelomerase activity at different time points during mDA neuron
differentiation of the human embryonic stem cell (hESC) line H9
using a well-established protocol (Kriks et al., 2011). Telomerase
activity was measured by the telomerase repeat amplification
protocol (TRAP). Using this method, we show that telomerase
is almost completely silenced by day 18 of the mDA differentia-
tion protocol (Figures 1A and 1B). We also measured telomerase
mRNA levels by qRT-PCR, showing a very small decrease in
TERC levels but a dramatic loss of TERT during differentia-
tion (Figure 1C). In parallel to the downregulation of telomerase,
we also observed telomere shortening during mDA neuronal
differentiation, as measured by high-throughput quantitative
FISH (HT Q-FISH) (Figures 1D–1F). There was both a decrease
in mean telomere length (Figure 1D) and an increase in the per-
centage of cells with short telomeres (Figure 1E).
Pharmacological Telomerase Downregulation in hPSC
The strategy selected to downregulate telomerase was its
pharmacological inhibition with the compound 2-[(E)-3-naphtha-
len-2-yl-but-2-enoylamino]-benzoic acid (BIBR1532), a small
molecule inhibitor of telomerase catalytic activity. First, we
tested whether the telomerase inhibitor BIBR1532 can inhibit
the activity of telomerase in undifferentiated H9 hESCs. Using
the TRAP assay, we confirmed that at concentrations of 10 mM
or higher the activity of telomerase was reduced to 50% of its
original activity (Figures 2A and 2B). Based on these results,
we used 10- and 40-mM concentration of BIBR1532 for treating
hPSCs with DMSO as a control. We treated H9 hESCs and two
PD iPSC cell lines with homozygous mutations in PINK1
(Q456X) and PARKIN (V324A), respectively, with the telomerase
inhibitor. A 2-week treatment induced telomere shortening in all
three hPSC lines, as measured by the HT Q-FISH method. We
observed both a decrease of the mean telomere length (Fig-
ure 2C) and an increase in the percentage of short telomeres
(Figure 2D) in the cells treated with the inhibitor. Telomere short-
ening induced by the telomerase inhibitor was also confirmed by
Southern blot of telomeric restriction fragments (TRFs) in the
three hPSC cell lines tested (Figures S1A–S1C). The increased
abundance of shorter telomeric fragments in treated cells can
be easily observed by comparing the profile lane of treated
and untreated cells (Figures S1A–S1C). We did not observe dra-
matic differences in pluripotency marker expression following
treatment with the inhibitor (Figures S2A–S2C). However, the
cells treated with both concentrations of the inhibitor showed
significantly less SSEA3 positive cells, with a decrease of around
20%compared to DMSO-treated control (Figure S2A). No signif-
icant differences in the percentage of NANOGpositive cells were
observed between treated cells and control (Figure S2B). In the
case of OCT4 (POU5F1), only the higher concentration of the
inhibitor significantly reduced the percentage of positive cells
compared to control cells (Figure S2C). In addition, cell-cycle
analysis showed a slight decrease in the percentage of cells in
S phase in BIBR1532-treated cells (Figure S2D). These results
indicate that pharmacological downregulation of telomerase
at the pluripotent stage results in telomere shortening with
some functional consequences for pluripotent cells including a
downregulation of some pluripotency markers and reduction in
proliferating cells.Cell Reports 17, 1184–1192, October 18, 2016 1185
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Figure 1. Telomere Dynamics in Neural Dif-
ferentiation
(A) TRAP polyacrylamide gel representing the
telomerase activity at different time points of the
mDA differentiation protocol. Two dilutions for
each sample (1 and 0.2 mg of protein) and a
negative control treated with RNase are included
as well as an internal PCR control (IC).
(B) Quantification of telomerase activity measured
by TRAP assay on cells at different time points of
mDA neurons differentiation protocol. Bars repre-
sent mean ± SEM of the two dilutions per sample.
(C) mRNA levels of TERC and TERT measured
by quantitative PCR. Data are represented as
mean ± SEM.
(D) Quantification of the mean ± SEM telo-
mere length measured by HT Q-FISH. Numbers
above bars indicate the number of telomere spots
quantified.
(E) Percentage of short telomeres (<8 kb)
measured by HT Q-FISH. Numbers above bars
indicate the number of short telomeres out of the
total number of telomeres.
(F) Representative HT Q-FISH images. Nuclei are
stained with DAPI (blue). Telomeres are stained
with CY3 (yellow).The Impact of Shortened Telomeres on Aging and
Disease-Related Phenotypes in hPSC-Derived Neurons
In order to generate hPSC-derived neurons with shortened
telomeres, we decided to pre-treat hPSC lines (H9, PINK1, and
PARKIN) with the telomerase inhibitor at the pluripotent stage
for 2 weeks and to maintain treatment during the differentiation
protocol until day 18. Cells were exposed to the telomerase in-
hibitor BIBR1532, at either 10 or 40 mM with DMSO treatment
serving as a control. To address whether the drug treatment
could interfere with mDA neuron differentiation efficiency, we
quantified the mDA neuron marker FOXA2 at day 30 of differen-
tiation (Figure S3A). Differentiation into FOXA2+ putative mDA
neurons occurred with high efficiencies independent of the
drug treatment (Figure S3A). Next, wemeasured telomere length
in the resulting neurons. The treatment with the telomerase inhib-
itor resulted in neurons with shorter telomeres assessed by
HT Q-FISH, reflected both by a decrease in the mean telomere
length (Figure 3A) and by an increase in the percentage of short
telomeres (Figure 3B) at day 65 of differentiation. In the PARKIN1186 Cell Reports 17, 1184–1192, October 18, 2016line, the 10-mM treatment group only
increased the percentage of short telo-
meres, while no decrease in the mean
telomere length was observed at this
concentration (Figures 3A and 3B). Those
data are compatible with the notion that
the percentage of short telomeres is a
more sensitive parameter than the mean
telomere length in individual cells (He-
mann et al., 2001; Vera et al., 2012;
Vera and Blasco, 2012). Telomere length
of hPSC-derived neurons from treated
versus untreated cultures was alsomeasured by Southern blot in the Parkin line to further validate
the Q-FISH data (Figure S1D). We observed an increase of
short telomeres in the neurons treated with the telomerase
inhibitor by analyzing the blot and comparing the lane profiles
(Figure S1D).
Finally, we tested whether neurons with shorter telomeres
exhibit other age-related markers. We measured several candi-
date age-associated phenotypes such as increased DNA dam-
age and a reduction in the number of dendrites per cells. DNA
damage measured by gamma H2AX intensity was increased in
the cells treated with the higher concentration of the inhibitor
across all three hPSC lines compared (Figures 3C and 3D). Pilot
studies suggest that mitochondrial ROS, as measured by the
percentage of MitoSox positive cells, may also be increased in
the PINK and PARKIN lines treated with the telomerase inhibitor
(Figure 3E). In addition, reduced dendrite numbers, labeled with
MAP2 dendrite marker, were observed in H9 for both BIBR1532
concentrations and in the PARKIN line when treated at the higher
concentration (Figures 4A and 4B). No reduction in dendrite
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Figure 2. Pharmacological Telomerase
Downregulation in hPSCs
(A) Quantification of telomerase activity levels
resulting from the treatment of H9 cells with
different concentrations of the telomerase inhibitor
BIBR1532, as determined using the TRAP assay.
Bars represent mean ± SEM. For comparative
purposes, TRAP values are represented as fold
decrease relative to those of the untreated sample
(0 mM of BIBR1532), which showed the highest
telomerase activity.
(B) Corresponding TRAP polyacrylamide gel. Two
dilutions for each sample (1 and 0.2 mg of protein)
and a negative control treated with RNase are
included as well as an internal PCR control (IC).
(C and D) H9 cells were treatedwith the telomerase
inhibitor BIBR1532 for 14–16 days. Two different
concentrations were included (10 and 40 mM) and
DMSO was used as a control. (C) Quantification of
the mean ± SEM telomere length measured by HT
Q-FISH. Numbers above bars indicate the number
of telomere spots quantified. (D) Percentage of
short telomeres (<8 kb) measured by HT Q-FISH.
Numbers above bars indicate the number of short
telomeres out of the total number of telomeres.number was observed in PINK cell line (Figure 4A). One potential
confounding factor for interpreting such age-related marker
expression in vitro is the possibility of negative selection for
those neurons with increased mitochondrial stress or reduced
dendrite number. However, in support of our data on dendrite
loss, in-vitro-differentiated neurons derived from the neural
stem cells (NSCs) of a G3 Terc KO mouse also have fewer neu-
rites. Therefore, the ability of neurons to extend neurites may be
linked to telomere function and chromosomal integrity. More-
over, this study shows that this effect could be rescued by P53
deletion indicating that it is P53 dependent (Ferro´n et al.,
2009). Altogether, our data support the idea that neurons with
short telomeres show an ‘‘older’’ cell phenotype.
We next wanted to test whether human embryonic stem
cells with shortened telomeres also exhibit age-related marker
expression upon differentiation into alternative lineages such as
cardiomyocytes. Similar to the neuronal differentiation studies,
telomerase was pharmacologically inhibited for the cardiomyo-
cyte study using the telomerase inhibitor drug BIBR1532. Cells
were treated with the telomerase inhibitor for 2 weeks previous
to starting the differentiation protocol, and treatment was
continued throughout the cardiomyocytes differentiation proto-
col. Interestingly, telomerase inhibition in cardiomyocytes re-
sulted in a lower percentage of cardiomyocytes, as shown by
a decrease in the percentage of TBX5 positive cells (Fig-
ure S4A). The fact that telomerase inhibition resulted in fewer
cardiomyocytes may indicate that telomerase activity is neededCell Repofor cardiomyocyte differentiation. Sup-
porting this idea, Bednarek et al. showed
in zebrafish that the absence of telome-
rase results in fewer cardiomyocytes
and impaired heart regeneration (Bed-
narek et al., 2015).Furthermore, the differentiated cardiomyocytes showed evi-
dence of increased DNA damage, as measured by gamma
H2AX intensity (Figure S4C), and shorter telomeres (Figures
S4E–S4G) as shown by a decrease in mean telomere length (Fig-
ure S4E) and an increase in the percentage of short telomeres by
HT Q-FISH (Figure S4F). The cardiomyocyte data support our
findings in neurons that telomere shortening can trigger age-
related marker expression in cells with no or minimal capacity
for cell proliferation.
In addition to the aging phenotypes observed, neurons with
shortened telomeres also show preliminary evidence for dis-
ease-specific phenotypes. In particular, neurons derived from
cells treated with the telomerase inhibitor exhibited a loss of
TH while maintaining other neuronal markers such as FOXA2 at
day 30 (Figures S3A and S3B) and day 65 of differentiation (Fig-
ures 4C–4E). Progressive loss of TH expression is a character-
istic feature of early PD at a stage when DA neurons are still alive
(Chaudhuri et al., 2006). These data are reminiscent of our previ-
ous findings in progerin expressing PD-iPSC-derived neurons
that show a loss of TH at 3 months after transplantation into
the adult mouse striatum (Miller et al., 2013). In conclusion, our
current study yields preliminary evidence that shortened telo-
meres in PD iPSC derived mDA trigger age- and disease-related
phenotypes. However, future studies will be required to further
validate those findings using genetic strategies of telomere
shortening and testing larger cohorts of patient-specific and
control lines.rts 17, 1184–1192, October 18, 2016 1187
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Figure 3. Shortened Telomeres Effect on
the Aging Phenotype of hPSC-Derived
Neurons
Different aging-associated phenotypes were
measured in H9 and two PD iPSC lines, PINK1 and
PARKIN-derived neurons, at day 65 of mDA dif-
ferentiation protocol. Cells were treated with two
different concentrations (10 and 40 mM) of the
telomerase inhibitor BIBR1532 and DMSO was
used as a control.
(A) Quantification of the mean ± SEM telomere
length measured by HT Q-FISH in hPSC-derived
neurons. Numbers above bars indicate the number
of telomere spots quantified.
(B) Percentage of short telomeres (<8 kb)
measured by HT qFISH in hPSC-derived neu-
rons. Numbers above bars indicate the number
of short telomeres out of the total number of
telomeres.
(C) Quantitative analysis of DNA damage measured
by the mean gamma H2AX intensity per nuclei
expressed in arbitrary units of fluorescence
(AUF). Bars are represented as mean ± SEM.
Numbers above bars indicate the number of nuclei
quantified.
(D) Representative images of gamma H2AX
immunofluorescence (orange).
(E) Mitochondrial ROS quantification, measured
by MitoSOX assay, analyzed by FACS. Numbers
above bars indicate the number of MitoSOX posi-
tive cells out of the total number of cells.DISCUSSION
Age is the primary risk factor for many neurodegenerative
disorders including PD. A late disease onset indicates that
the genetic mutation provides susceptibility but is not suffi-
cient to trigger the disease. Accordingly, most iPSC models
show evidence of biochemical changes that are directly
linked to the disease-specific mutation but lack age-associ-
ated features such as spontaneous neuronal degeneration.
Taking one additional step forward, we have recently pre-
sented a strategy to genetically trigger age-like features in
iPSC derivatives toward modeling of a late-onset disease
by engineering the overexpression of progerin in iPSC-
derived mDA neurons (Miller et al., 2013). However, the ques-
tion of whether targeting pathways that trigger progeroid syn-
dromes mimics pathological over physiological aging remains
to be resolved.
Here, we present an alternative, potentially more physiological
approach to induce aging by altering one of the classic ‘‘hall-
marks’’ of aging, telomere shortening. In the present study, we
show that telomerase is downregulated and telomeres get
shorter during neuronal differentiation and that the telomeres
of hPSC and hPSC derivatives can be further shortened using
a pharmacological approach. We then demonstrate that hPSC
derived neurons with shorter telomeres present age-like features
such as increased DNA damage, mitochondrial ROS, and1188 Cell Reports 17, 1184–1192, October 18, 2016reduced dendrite numbers and preliminary disease-related fea-
tures such as TH loss.
While telomere shortening by pharmacological inhibition was
reproducible across experiments, as shown both by HT Q-FISH
and by Southern blot (Figures 2C, 2D, 3A, 3B, and S1A–S1D),
we observed some variability in the readout of absolute telomere
length within the same cell line across experiments. This vari-
ability in absolute telomere length is inherent to any biological
cell population and can fluctuate in undifferentiated hPSCs de-
pending on passage and culture conditions. Interestingly, we
also observed some variability in telomere length among the
various hPSC cell lines (Figures 2C, 2D, 3A, 3B, and S1A–S1C),
which may reflect the high interindividual variation of telomere
length across human populations (Canela et al., 2007). Impor-
tantly, as shown in Vera et al. (2012), the rate of increase in the
percentage of short telomeres over time (slope), and not the
absolute telomere length, is a significant predictor of lifespan in
mice. These results indicate that the measure of telomere short-
ening most relevant to aging may be the rate of change in each
individual and consequently in each cell line. Based on this argu-
ment, we propose that a key feature of the current study is the
effort to ‘‘age’’ each cell line independently, triggering a relative
increase in the percentage of short telomeres.
There are several major limitations for the use of small mole-
cules in regulating telomerase activity. For example telomerase
activity is reduced rather than being shut down completely.
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Figure 4. Shortened Telomeres Effect on the Neuronal Aging, Differentiation Efficiency, and Disease-Related Phenotype of hPSC-Derived
Neurons
Neuronal aging, differentiation efficiency, and disease-associated phenotypes were measured in H9 and two PD iPSC lines, PINK1 and PARKIN-derived neurons
at day 65 of mDA differentiation protocol. Cells were treated with two different concentrations (10 and 40 mM) of the telomerase inhibitor BIBR1532 and DMSO
was used as a control.
(A) Quantitative analysis of MAP2 dendritic marker measured by the number of dendrites per cell. Bars represent mean ± SEM. Numbers above bars indicate the
number of nuclei quantified.
(B) Representative images of MAP2 (orange) marker of hPSC-derived neurons.
(C) Quantitative analysis of FOXA2 (mDA marker) immunofluorescence. Numbers above bars represent the number of positive nuclei over the total number of
nuclei analyzed.
(D) Quantitative analysis of FOXA2 and TH (mDAmarker lost in early stage of Parkinson’s disease) double positive cells in immunofluorescence images. Numbers
above bars represent the number of positive nuclei over the total number of nuclei analyzed.
(E) Representative images of TH (green) and FOXA2 (red) staining of hPSC-derived mDA neurons.Therefore, the extent of telomere shortening is fairly modest,
even though it was enough to trigger age- and disease-related
phenotypes. Furthermore, the impact and mechanism of telo-
mere shortening in postmitotic cells remains to be explored.
Our current study represents a proof of concept for the useof telomere shortening as an ‘‘induced aging’’ strategy sui-
table for iPSC-based disease modeling. However, it will be
important in future studies to test the full impact on age- and dis-
ease-related phenotypes using more precise genetic strategies
of manipulating telomere length. Finally, it will be interesting toCell Reports 17, 1184–1192, October 18, 2016 1189
directly compare various emerging ‘‘induced aging’’ technolo-
gies (Studer et al., 2015) to determine those most suitable
and effective at modeling late-onset disease in iPSC-based
studies.
EXPERIMENTAL PROCEDURES
HT Q-FISH
Cells were plated on a clear-bottom, black-walled, 96-well plate, including
4-well replicates per sample, and HT Q-FISH was performed as previously
described (Canela et al., 2007). Images were captured with the Operetta
high-throughput automated microscope (PerkinElmer). Telomere length
values were analyzed using individual telomere spots (>1,800 per sample),
and fluorescence intensities were converted into kilobases as described
previously (Canela et al., 2007; McIlrath et al., 2001).
Telomerase Assay
The telomerase activity was measured with a modified TRAP (Garcı´a-Cao
et al., 2002). As control for PCR efficiency, an internal control (IC) was
included in each reaction (TRAPeze kit, Oncor). The main modification is
that radioactive-labeled TS primer was substituted by a fluorescent CY5-
labeled TS primer. Protean II (Bio-Rad) electrophoresis chamber was
used to run the Accrilamide: Bisacrilamide 19:1 gels. Fluorescent gels
were not dried and were imaged wet instead in Typhoon FLA700 laser
scanner. Digitalized images were quantified by using ImageJ software.
The ‘‘sum intensity’’ was calculated for each lane. Two dilutions were
made for each sample (1 and 0.2 mg). The RNase-treated sample was
used to quantify the background and subtracted to each sample value.
Telomerase activity values, expressed in arbitrary units (a.u.) were then
multiplied by the dilution factor and normalized by the day 0 (Figure 1B)
or 0-mM-treated (Figure 2A) sample. For testing telomerase inhibition by
BIBR1532 (Figure 2B), the protein extracts were preincubated with the indi-
cated concentration of BIBR1532 for 15 min on ice before the telomerase
reaction was performed.
Pluripotent Stem Cell Culture and iPSC Differentiation
Undifferentiated hESCs (H9/WA-09) and iPSCs were cultured on mitotically
inactivated mouse embryonic fibroblasts (MEFs) in ESC media containing
20% knockout serum replacement (KSR) as previously described (Kriks
et al., 2011). MDA neuron differentiations were performed as previously
described (Kriks et al., 2011). Cardiomyocyte differentiation was done
following a modified version of the previously described protocol (Laflamme
et al., 2007). Briefly, the hESCs were dissociated into single cells using
0.05% trypsin and cultured in ultra-low cluster 6-well plates (2 million
cells/well) in hESC media containing Y-drug (Y-27632). The cells aggregate
into embryoid bodies (EBs) and grow for 6 days before they are plated on
gelatin coated wells. At this point, the hESC medium is replaced with
RPMI medium supplemented with B27 and Activin A (100 nM). The media
are replaced the next day with RPMI supplemented with B27 and BMP4
(10 nM). The cells are cultured in BMP4 containing medium for a total of
four days and mature further in the same RPMI+B27 medium without any
additional growth factors.
Flow Cytometry, mtROS, and Cycle Analyses
Cells were dissociated with Accutase (Innovative Cell Technologies) and
stained with directly conjugated antibodies (BD Biosciences). The antibody
used for flow cytometry was SSEA3 (Sigma). For mitochondrial reactive oxy-
gen species (mtROS) assessment, cells were stained with MitoSOX Red
(Life Technologies) at a final concentration of 20 mM in cell-culture medium.
Cell sorting was performed on a FACSAria (BD Biosciences). For cell-cycle
analysis, cells were collected in PBS and fixed in cold 70% ethanol. Followed
by RNase A (Ambion) treatment, cells were stained with propidium iodide
(50 mg/ml, Invitrogen) in PBS and subjected to fluorescence-activated cell
sorting (FACS) analysis according to standard procedures. For post-sort anal-
ysis, data were processed using FlowJo (Tree Star) software.1190 Cell Reports 17, 1184–1192, October 18, 2016qRT-PCR Analysis
Cells were lysed with TRIzol (Life Technologies), treated for DNA contamina-
tion, and reverse-transcribed using QuantiTect RT kit (QIAGEN). The mRNA
levels were assayed using the SYBR Green PCR kit (QIAGEN) on a Master-
Cycler RealPlex2 (Eppendorf). All results were normalized to a GAPDH control.
The primers used are detailed in Supplemental Experimental Procedures.
Immunostaining
Cells were fixed by incubation in 4% paraformaldehyde for 15 min and incu-
bated in blocking buffer (0.3% Triton X-100 in PBS) for 30 min. Cells were
stained with primary antibodies in PBS supplemented with 1% BSA at 4C
overnight, washed, and stained with secondary antibodies in PBS supple-
mented with 0.1% BSA for 1 hr at room temperature, in the dark. Nuclei
were stained by DAPI (Invitrogen). The following primary antibodies were
used: TH (1:1,000; Pel Freeze), FOXA2 (Santa Cruz Biotechnology; 1:200),
OCT4 (1:100; Santa Cruz), NANOG (1:50; R&D), and phospho-Histone
H2A.X (Ser139; clone 20E3; 1:400; Cell Signaling Technology).
Telomere Restriction Fragment Analysis
Cells were harvested by trypsin treatment, washed with PBS, pelleted, and
frozen at80C for genomicDNAcollection.GenomicDNAwas extracted us-
ingQIAampDNAMini Kit (QIAGEN). DNAwasdigestedwithMboI andAluI and
quantitated by fluorometry using Hoechst 33258, and 100 ngwas loaded on a
0.5%agarose gel run in 0.53TBE. The gelswere depurinatedwith 0.25NHCl,
denatured, and neutralized using standard Southern blotting procedures. The
DNA was transferred to Hybond-N membrane (Amersham) in 20 3 SSC and
cross-linked by UV exposure in a Stratalinker (Stratagene). Membranes
were hybridized overnight at 65C in Church mix (0.5 M sodium phosphate
buffer [pH 7.2], 1mMEDTA, 7%SDS, 1%BSA)with a 800-bp TTAGGG repeat
fragment Klenow-labeled using a 50CCCTAACCCTAA-30 primer and a-32P-
dCTP/dATP. Post-hybridization washes were performed in 40 mM Na-phos-
phate buffer (pH 7.2), 1 mM EDTA, and 1% SDS at 65C. Membranes were
exposed to PhosphorImager screens. To generate the lane profile graph,
gray values were obtained in ImageJ and plotted as the percentage of the
maximum intensity value of the lane.
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